Drugs / Antigen-specific IgT cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03170141 | May 2017 → Jul 2027 expected | brain glioblastoma | Shenzhen Geno-Immune Medical Institute | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antigen-specific IgT cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03170141 ↗ |
| Modality | Cell therapy | “autologous GD2-specific 4SCAR-T cells” PMID 36617554 ↗ Jan 2023 |
| Route | Intravenous | “Tumor antigen-specific IgT cells are infused intravenously .” NCT03170141 ↗ |